Upgrades

PharmScreen updates

Posted on

PharmScreen evolves day by day thanks to the feedback of many computational and medicinal chemists! We have been incorporating different features to our 3D virtual screening tool. Have a look to the latest updates! Major updates Field visualization: Now you are able to visualize the different molecular fields of your reference compound as well as […]

Partnerships

Machine Learning partnership to accelerate discovery of novel drugs

Posted on

CCDC and Pharmacelera combine virtual screening and machine learning expertise to help scientists accelerate drug discovery Barcelona and Cambridge, UK, 26th June 2019. The Cambridge Crystallographic Data Centre (CCDC) and Pharmacelera have reached an agreement to perform a joint research project to reinforce the results obtained by structure-based in-silico technologies via ligand-based tools. GOLD, CCDC’s docking software used […]

News

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

Posted on
Pharmacelera agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson based on the work led by Dr. Salvador Ventura and developed at Institut de Biotecnologia i Biomedicina (IBB). PharmScreen®, Pharmacelera’s flagship software, will be used to perform screening campaigns in huge virtual libraries […]

Science

Alignment of PIM-1 Inhibitors with PharmScreen

Posted on

Pim-1 is an oncogene-encoded serine/threonine kinase. Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with survival an proliferation which confers a selective advantage during tumorigenesis [1,2]. Given this implication, it has been used as a cancer drug target [3]. IYZ and LY2 are two bioactive inhibitors of Pim-1. The […]